Biotronik wins FDA nod for Acticor, Rivacor high-voltage tachycardia devices
Biotronik said yesterday it won FDA approval for its Acticor and Rivacor high-voltage cardiac rhythm management devices intended for treating patients with cardiac arrhythmias. The clearance covers the Berlin, Germany based company’s Rivacor VR-T, Rivacor DR-T, Rivacor HF-T QP, Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX devices. “When determining the best treatment plan for each patient, we assess individual needs and select a device system that provides optimal therapy programming with critical diagnostic features. We are often forced to choose between important features, which could compromise opti...
Source: Mass Device - March 15, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Featured Food & Drug Administration (FDA) Regulatory/Compliance Biotronik Source Type: news
Biotronik Has a New DES Added to its Repertoire
FDA has just signed off on Biotronikâs Orsiro drug-eluting stent (System). The Lake Oswego, OR-based company claims the stent is the first and ultrathin DES to outperform Abbott Laboratoriesâ, Xience stent, which is known as the clinical standard. Biotronik said its first implants will occur this week and that it will be available in health systems in the early part of this year. The company has had CE mark for Orsiro since 2011. Perhaps the biggest selling point of the technology is the ultrathin strut design. âThinner struts are different in that they potentially crea...
Source: MDDI - February 25, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news
Risk of cardiac arrhythmias after electrical accident: a single-center study of 480 patients - Pilecky D, Vamos M, Bogyi P, Muk B, Stauder D, Racz H, Nyolczas N, Duray GZ, Zacher G, Zima E.
OBJECTIVE: Patients with electrical injury are considered to be at high risk of cardiac arrhythmias. Due to the small number of studies, there is no widely accepted guideline regarding the risk assessment and management of arrhythmic complications after el... (Source: SafetyLit)
Source: SafetyLit - February 18, 2019 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news
These medtech companies raised the most VC in 2018
[Image from unsplash.com]Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively. The third and fourth quarters were slightly lower, with medtech companies raising $738 million in Q3 and nearly $641 million in Q4. There were 218 deals in 2018, a slight decrease from the 229 deals involving me...
Source: Mass Device - February 15, 2019 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News venture capital Source Type: news
J & J ’ s Biosense Webster launches IDE-cleared Qdot Micro RF ablation trial
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster said yesterday it launched a new FDA investigational device exemption study of its Qdot Micro radiofrequency ablation catheter exploring its use in treating symptomatic drug-refractory paroxysmal atrial fibrillation. The first patient in the trial has already been treated, with the procedure taking place at NYU Langone Health’s Heart Rhythm Center, the Irvine, Calif.-based J&J division said. “The delivery of 90 watts of RF power in a short, four-second ablation session is a significant advancement in the treatment of paroxysmal atrial fibri...
Source: Mass Device - February 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Food & Drug Administration (FDA) johnsonandjohnson Source Type: news
Prolonged QT syndrome due to donepezil: a reversible cause of falls? - Jackson EG, Stowe S.
We report a case of prolonged QT syndrome caused by donepezil which resulted in a fall and hip fracture. In this case... (Source: SafetyLit)
Source: SafetyLit - January 21, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
iRhythm Finds Its Groove at the Intersection of Cardiology and AI
iRhythm Technologies has the distinct feature of being at the intersection of some of the hottest markets in medtech â cardiology, wearables, and artificial intelligence. The San Francisco-based company has developed, the Zio Patch XT, a wearable technology to monitor heart rate activity for up to 14 days and is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week. Tim King, iRhythmâs president and CEO spoke to MD+DI ahead of the companyâs presentation about the company's success and its goals going forward. âThe tool of choice...
Source: MDDI - January 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Digital Health Source Type: news
New study shows link between secondhand smoke and cardiac arrhythmia
(University of California - Davis Health) Continuous indoor exposure to secondhand tobacco smoke triggers changes in the heart's electrical activity, known as cardiac alternans, that can predict cardiac arrhythmia and sudden cardiac death, a new study from UC Davis Health researchers shows. The authors believe the study, conducted in mice, suggests that secondhand smoke exposure alters cells that regulate how the heart beats. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 26, 2018 Category: International Medicine & Public Health Source Type: news
Cardiva Medical wins FDA PMA for Vascade MVP vascular closure device
Cardiva Medical said today it won FDA premarket approval for its Vascade MVP venous vascular closure device. The Vascade MVP system is composed of a thrombogenic bioabsorbable collagen patch and a collapsible mesh disc, the Santa Clara, Calif.-based company said. The device functions by placing a collapsible mesh disc against the inner vessel wall to stop bleeding followed by a collagen patch and the removal of the mesh disc, the company said. The collagen patch is designed to expand, seal and stop bleeding and is later absorbed by the body. Cardiva touted the Vascade MVP as the first and only vascular closure system ...
Source: Mass Device - December 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Pre-Market Approval (PMA) Regulatory/Compliance Vascular Cardiva Medical Inc. Source Type: news
J & J ’ s Biosense Webster launches Heliostar multi-electrode ablation cath trial
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster said this week that it enrolled and treated the first patient in its Stellar U.S. investigational device exemption study. The 640-patient trial is designed to assess the safety and efficacy of the Heliostar multi-electrode radiofrequency balloon ablation catheter as a treatment for drug refractory recurrent paroxysmal atrial fibrillation. The Heliostar device features 10 electrodes and is designed to allow electrophysiologists to achieve pulmonary vein isolation with a single application of RF energy, according to Biosense Webster. Cardiac electrophysiologists Drs. ...
Source: Mass Device - November 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Catheters Clinical Trials Featured Wall Street Beat Biosense Webster johnsonandjohnson Source Type: news
J & amp;J Subsidiary Launches IDE Study for AF
A new U.S. study aims to evaluate a radiofrequency (RF) balloon ablation catheter for the treatment of symptomatic drug refractoryÂ recurrent paroxysmal (intermittent) atrial fibrillation. Biosense Webster, a subsidiary of Johnson & Johnson, said the investigational device exemption study will enroll up to 640 patients at as many as 40 clinical sites worldwide. The STELLAR studyÂ will evaluate the company's HeliostarÂ RF balloon ablation catheter. "This new balloon catheter is unique because it conforms to any pulmonary vein anatomy and allows me to control electrodes individually ...
Source: MDDI - November 29, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
BioSig inks Pure EP first-in-human study deal with Texas Cardiac Arrhythmia Institute
BioSig Technologies (OTCQB: BSGM) said today that it inked a deal with Austin’s Texas Cardiac Arrhythmia Institute at St. David’s Medical Center to launch first-in-human studies using its Pure EP system. The Santa Monica, Calif.-based company’s Pure EP system is designed for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures. The device is intended to reduce noise and artifacts to produce high-fidelity cardiac signals, which the company claims...
Source: Mass Device - November 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Clinical Trials BioSig Technologies Source Type: news
Abbott Initiates Study to Evaluate Ablation as a Frontline Treatment for Patient's Suffering from a Common but Complex Cardiac Arrhythmia
LESS-VT Study is the first U.S. clinical trial to evaluate the safety and effectiveness of ablation treatment for patients with monomorphic ventricular tachycardia, a common heart rhythm disorder (Source: Abbott.com)
Source: Abbott.com - November 20, 2018 Category: Pharmaceuticals Source Type: news
The association between unexplained falls and cardiac arrhythmias: a scoping literature review - Wiseman T, Betihavas V.
BACKGROUND: Falls in older adults are common. Age is a risk factor for falls and with an ageing population, presentation to the emergency department (ED) resulting from falls is rising. Reasons for falls in older adults are numerous and include cardiac arr... (Source: SafetyLit)
Source: SafetyLit - November 16, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Cardiva touts results from pivotal Vascade MVP vascular closure device trial
Cardiva Medical today released results from the pivotal study of its Vascade MVP vascular closure device intended for multi-access venous closure following electrophysiology procedures, touting that the trial met its primary and secondary endpoints. The results from the AMBULATE trial were presented today at the American Heart Association’s annual Scientific Sessions by Texas Cardiac Arrhythmia Institute exec medical director Dr. Andrea Natale. The Vascade system is composed of a thrombogenic bioabsorbable collagen patch and a collapsible mesh disc, the Santa Clara, Calif.-based company said. The device fun...
Source: Mass Device - November 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Cardiva Medical Inc. Source Type: news
Preventing sudden cardiac death with genome editing
(Baylor College of Medicine) Gene editing successfully prevented sudden cardiac death in a mouse model of inherited cardiac arrhythmia disorder. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 30, 2018 Category: Biology Source Type: news
FDA approves Abbott ’ s HeartMate 3 as a destination therapy
Abbott (NYSE:ABT) said today it won FDA approval for its HeartMate 3 left ventricular assist device, now approved as a destination therapy for patients with advanced heart failure. With the approval, the Chicago-based company said that the device can now be used in patients not eligible for a transplant as a life-long implant. “We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes. The unique design of the HeartMate 3 LVAD—with its Full MagLev technology—takes an established innovation and improves upon it in meaningful ways to help people with...
Source: Mass Device - October 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news
Pins and needles: How acupuncture can help soothe an irregular heartbeat
(Natural News) Cardiac arrhythmia describes an irregular heartbeat caused by an interruption of electrical impulses in heart function. This group of conditions can be further broken down into bradycardia (slow heartbeat), tachycardia (fast heartbeat), flutter or fibrillation (irregular heartbeat), or premature contraction (early heartbeat). While most types of heart arrhythmia are relatively harmless (caused by... (Source: NaturalNews.com)
Source: NaturalNews.com - October 6, 2018 Category: Consumer Health News Source Type: news
Judge pares claims in Bard IVC bellwether
A federal judge in Arizona yesterday pared some claims in the third bellwether case involving inferior vena cava filters made by Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard, as the trial entered its 11th day. It’s the fourth bellwether in the multi-district litigation over the IVC devices, which are designed to prevent blood clots from passing through the body’s largest vein into the heart and lungs. In the first case to go to trial, a federal jury in Phoenix found for plaintiff Sherr-Una Booker, awarding $3.6 million in damages. Bard prevailed in the second bellwether trial, with the jury findin...
Source: Mass Device - October 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Legal News Product Liability Vascular bectondickinson crbard Source Type: news
InfoBionic drums up $50m for MoMe Kardia remote heart monitor
InfoBionic said today that it raised another $50 million for its wireless remote cardiac monitor. Boston-based InfoBionic said Eagle Investments, Excel Venture Management, Safeguard Scientifics, Blue Cross Blue Shield of Massachusetts subsidiary Zaffre Investments and Blue Cross and Blue Shield of Kansas all participated in the round. The company sells the MoMe Kardia device, a remote, wireless outpatient system for monitoring & diagnosis of cardiac arrhythmias. It won 510(k) clearance from the FDA in 2015. Last month, InfoBionic inked a deal giving exclusive U.S. distribution rights for the MoMe Kardia syste...
Source: Mass Device - September 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Patient Monitoring Wall Street Beat InfoBionic Source Type: news
Biotronik Enters into Distribution Agreement with InfoBionics
Biotronik has become the exclusive US distributor for InfoBionic's MoMe Kardia external cardiac diagnostic monitor. The device benefits patients suspected of experiencing cardiac arrhythmias. âWhen weâre looking at partners -Â weâre asking ourselves -Â are these partners able to do the three main things that are important to us,â Rupa Basu, Senior Vice President of Marketing, Corporate Accounts and Strategy, at Biotronik, told MD+DI. âThe first thing is, is it going to improve the patientâs expe...
Source: MDDI - September 7, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
Biotronik to distribute InfoBionic monitor in U.S.
Biotronik has landed exclusive U.S. distributorship for InfoBionic’s MoMe Kardia external cardiac diagnostic monitor. MoMe Kardia was designed to increase early detection and diagnosis of cardiac arrhythmias by providing physicians with the ability to access near real-time electrocardiographic data. Monitoring can also uncover patients at higher risk of sudden cardiac death. Get the full story on our sister site, Medical Design & Outsourcing. The post Biotronik to distribute InfoBionic monitor in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Cardiac Assist Devices Distribution Biotronik InfoBionic Source Type: news
Bankers in their twenties suffering more heart attacks, doctors warn
These unlikely patients regularly present themselves with two types of heart conditions: cardiac arrhythmia and myocarditis. (Source: the Mail online | Health)
Source: the Mail online | Health - August 6, 2018 Category: Consumer Health News Source Type: news
The future of Abbott ’ s electrophysiology business
At DeviceTalks Minnesota 2018, medtech veteran Michael Pederson provided an inside look at the Abbott-St. Jude Medical merger and what’s ahead for Abbott’s cardiovascular technologies. Pederson tracked his career from a formative stint at HP to his current role as SVP of cardiac arrhythmias and heart failure at Abbott (NYSE:ABT). Check out his keynote address with DeviceTalks founder Brian Johnson. To learn more from the brightest minds in medtech, don’t miss DeviceTalks Boston on Oct. 8-10 The post The future of Abbott’s electrophysiology business appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Cardiovascular DeviceTalks Q&A Wall Street Beat Abbott DeviceTalks Boston DeviceTalks Minnesota Source Type: news
Johnson & Johnson hits the Big Apple with latest JLabs site
Johnson & Johnson (NYSE:JNJ) opened its latest life science incubator in New York City, the healthcare giant said today. The 30,000-square-foot JLabs @ NYC is a collaboration between Johnson & Johnson Innovation, New York State and the New York Genome Center. Sited at the genome center in SoHo, the incubator is home to 26 startups and has room for four more, New Brunswick, N.J.-based J&J said. “Johnson & Johnson has deep entrepreneurial roots in New York and we are pleased to see our unique JLabs model applied in this rich ecosystem to foster the creation of new healthcare innovations that have t...
Source: Mass Device - June 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Research & Development johnsonandjohnson Source Type: news
Philips acquires Remote Diagnostic Technologies
Royal Philips (NYSE:PHG) said today it acquired U.K.-based Remote Diagnostic Technologies for an undisclosed amount. Remote Diagnostic Technologies develops cardiac therapy, data management and monitoring solutions for the pre-hospital market, and has a portfolio of connected emergency care solutions that Amsterdam-based Philips said will complement its therapeutic care biz. “We are committed to investing in and expanding our resuscitation and emergency care offering, and with the acquisition of RDT we can boost our capabilities and portfolio in this vital area of healthcare. With its focus on the pre-hospi...
Source: Mass Device - June 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Patient Monitoring royalphilips Source Type: news
Philips to acquire EPD solutions in $293m upfront deal
Royal Philips (NYSE:PHG) said today it inked a deal to acquire image-guided cardiac arrhythmia treatment dev EPD Solutions for $293 million (EU €250 million) upfront with a possible additional $246.2 million (EU €210 million) upon completion of the deal based on certain milestones. EPD Solutions produces cardiac imaging and navigation systems designed to aid electrophysiologists in navigating the heart through a detailed 3D image of the cardiac anatomy, Amsterdam-based Philips said. The system is also designed to identify the location and orientation of catheters during the diagnostic and therapeutic pr...
Source: Mass Device - June 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Mergers & Acquisitions royalphilips Source Type: news
Philips Bets Big on Image-Guided Therapy with Latest Acquisition
Royal Philips is seeking to expand its image-guided therapy solutions with the acquisition EPD Solutions. Philips is set to acquire the Tortola, British Virgin Islands-based company for about $292 million upfront. The deal could close in July, Philips said. EPD’s cardiac imaging and navigation system has received CE mark and is used in diagnostic and therapeutic procedures for cardiac arrhythmias. The system has not been given a nod from FDA and is currently under review by the agency. Philips said its interventional imaging systems, such as Azurion, and EPD’s cardiac imaging and navigation system could more ef...
Source: MDDI - June 5, 2018 Category: Medical Devices Authors: Omar Ford Tags: Imaging Cardiovascular Source Type: news
Boston Scientific touts safety, effectiveness in Rhythmia mapping study
Boston Scientific‘s (NYSE:BSX) Rhythmia mapping system and catheter was found to be safe and effective in procedures to treat arrhythmias, according to a Healio summary of a newly released study from the company. Researchers in the study examined 572 patients, with 519 patients undergoing procedures with the Rhythmia system and IntellaMap Orion catheter, according to the report. A total of 504 patients had a complete mapping procedure and were followed for one month post-procedure. Findings from the study were presented at the EHRA 2018 meeting, according to Healio. The primary endpoint of the trial was acute procedu...
Source: Mass Device - May 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Imaging Boston Scientific Source Type: news
New Cardiac Mapping Options for Complex Arrhythmias
CARLSBAD, Calif., May 8, 2018 /PRNewswire/ -- Acutus Medical®, a global heart rhythm technology company, today announced that the AcQMap® High Resolution Imaging and Mapping System has been utilized for the first time in U.S. patients. The company also revealed initiation of a new clinical study to evaluate the technology during atrial fibrillation retreatment ablation procedures in Europe and Canada. "Enabling physicians to see complex, irregular arrhythmias in real-time should provide important new insights and enable truly personalized and individualized abla...
Source: MDDI - May 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Imaging Source Type: news
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
ADVISOR HD GRID MAPPING CATHETER, SENSOR ENABLED FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS FIRST-OF-ITS-KIND GRID CONFIGURATION IS DESIGNED TO CAPTURE DATA IN MULTIPLE DIRECTIONS T... Devices, Cardiology, FDA Abbott, Advisor, HD Grid Mapping Catheter, Arrhythmia, electrophysiology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 3, 2018 Category: Pharmaceuticals Source Type: news
For this Abbott executive, solving problems isn ’ t enough: ‘ We need to add value ’
As payers and providers across healthcare shift their focus to value-based care, leaders in the medical device industry are racing to keep up. Michael Pederson, SVP of cardiac arrhythmias and heart failure at Abbott, told MassDevice.com why simply solving problems with new technology isn’t enough anymore. What was your path like from electrical engineering to Abbott’s cardiac arrhythmia business? Pederson: As an engineer, I’ve always been drawn to how technology can evolve and re-shape entire industries. In particular, health technology can fundamentally change the lives of people battling complex health ...
Source: Mass Device - May 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Wall Street Beat Abbott devicetalksminnesota Source Type: news
Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter
- ADVISOR ™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS (Source: Abbott.com)
Source: Abbott.com - May 3, 2018 Category: Pharmaceuticals Source Type: news
Concerns Over Tick, Mosquito-Borne Diseases Rise After CDC Report
BOSTON (CBS) — A Center for Disease Control and Prevention (C.D.C.) report is raising concerns. From 2004-2016 the amount of tick, mosquito, and flea-transmitted diseases have tripled in the U.S. Nearly 60% of the diseases detected came from ticks. Dr. David Crandell, clinical co-director for the Dean Center Tick-Borne Illness at Spaulding Rehabilitation Hospital, says he’s not surprised. Dr. Crandell believes an increase in Lyme disease diagnosis comes from better testing and more importantly, a better understanding of the disease and the signs. He says symptoms include: Malaise, almost like a flu-like symptom...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 3, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated Local CDC Gary Brode Local TV Mosquitoes tick-borne disease ticks Source Type: news
Substance in Chinese medicine can cause cardiac arrhythmia
(University of Basel) A medicinal plant frequently used in Traditional Chinese Medicine (TCM) -- Evodia rutaecarpa -- contains substances that can cause cardiac arrhythmia. This is what researchers from the Universities of Basel, Vienna and Utrecht have recently found out. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 2, 2018 Category: Biology Source Type: news
Reconstructing what makes us tick
(American Institute of Physics) A major issue that limits modeling to predict cardiac arrhythmia is that it is impossible to measure and monitor all the variables that make our hearts tick, but researchers have now developed an algorithm that uses artificial intelligence to model the electrical excitations in heart muscle. Their work, appearing in Chaos, draws on partial differential equations describing excitable media and echo state networks to cross-predict variables about chaotic electrical wave propagations in cardiac tissue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2018 Category: International Medicine & Public Health Source Type: news
Coffee, Tea Not Necessarily Hazard to Heart Rhythm (CME/CE)
(MedPage Today) -- But cardiac arrhythmia patients should steer clear of energy drinks (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 17, 2018 Category: Primary Care Source Type: news
Cardiva Medical adds $11m for vascular closure devices
Cardiva Medical said yesterday that it added another $11 million to a funding round it closed last year at $30 million to continue the commercialization of its Vascade vascular closure device. Existing debt and equity investors participated, including PTV Healthcare Capital, Canepa Healthcare and affiliates of Luther King Capital Mgmt., the Santa Clara, Calif.-based company said. In March 2017 Cardiva said it had put a bow around the $30 million round for Vascade, which won 510(k) clearance from the FDA in February 2013. Yesterday the company said the latest infusion will also go toward its Ambulate investigation...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Vascular Wall Street Beat Cardiva Medical Inc. Source Type: news
High blood pressure - these vitamin supplements will lower your risk of heart attacks
Vitamin D supplements could help to reverse damage to blood vessels after suffering from high blood pressure, scientists have revealed. Cardiovascular damage increases the risk of deadly cardiac arrhythmia. (Source: Daily Express - Health)
Source: Daily Express - Health - January 31, 2018 Category: Consumer Health News Source Type: news
Philips joins $9m round for remote-care co LindaCare
Digital health company LindaCare has landed an $8.7 million Series B round, with investments made by Philips (NYSE:PHG), PMV, Capricorn ICT Arkiv, Connecticut Innovations and others. The Belgium-based company said it plans to use the newly-acquired funds to accelerate its U.S. market expansion and product commercialization, as well as build out its existing patient monitoring software platform for a broader range of cardiac diseases. “This investment is a significant step for us, as it enables LindaCare to execute faster on our ambitious vision and strategy, and to take a leading market position across both...
Source: Mass Device - January 24, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Patient Monitoring lindacare royalphilips Source Type: news
Cyclizine is sold in Denmark as an over-the-counter drug and has serious side effects when overdosed - Petersen K, Hjorth P.
Cyclizine is sold in Denmark as an over-the-counter drug and affects not only histaminergic but also muscarinergic, serotonergic and α-adrenergic receptors, with side effects such as respiratory depression and cardiac arrhythmias, leading to fatalities. D... (Source: SafetyLit)
Source: SafetyLit - January 18, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
The Startup Caf é, the Place where Healthcare IT Decision-Makers and New Companies can Meet
17 - 19 April 2018, Berlin, Germany. Whether they develop apps that detect the early stages of cardiac arrhythmia or cybersecurity software for hospitals, startups in the healthcare IT sector are flexible, highly innovative and can make a significant contribution to digitalising the healthcare system. (Source: eHealth News EU)
Source: eHealth News EU - January 16, 2018 Category: Information Technology Tags: Featured Events Conferences and Events Source Type: news
Abbott Expands Portfolio of MRI-Ready Devices
FDA gave MR-conditional labeling to two of Abbott's cardiac rhythm management (CRM) devices, a move that further boosts the company's ability to compete with its peers in the space. The Abbott Park, IL-based firm said patients who receive a Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) or a Fortify Assura implantable cardioverter defibrillator (ICD) are now able to have an MRI in the future if need be. The Quadra Assura and the Fortify Assura are two of Abbott's most widely-used high voltage devices, the company noted. In September 2016, Abbott won FDA approval for MR-conditional labeling for the...
Source: MDDI - January 3, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Regulatory and Compliance Source Type: news
The 8th Annual Alexander Awards: The Best Tox Reading of 2017
Alexander Gettler Once again, last year’s outstanding examples of long-form journalism dealing with topics related to medical toxicology were dominated by coverage of the opioid crisis, its origins and the resulting carnage. The must-read article of the year was “The Family That Built a Empire of Pain,” Patrick Radden Keefe’s massive history of the Sacklers, one of America’s richest clans, much of whose wealth comes from their ownership of Purdue Pharma and the marketing and distribution of Oxycontin. The article, which appeared in the New Yorker, notes that the clan’s patriarch, Ar...
Source: The Poison Review - January 2, 2018 Category: Toxicology Authors: Leon Gussow Tags: Medical 2017 Alexander awards opioids Purdue Pharma Sackler Source Type: news
Researchers are developing light therapy as a non-invasive, alternative treatment for disease
(Natural News) Artificial light has both its risks and benefits, but a new study shows that it may be the solution to minimally invasive, drug-free treatments. Researchers are currently developing new ways using infrared neuromodulation to treat cardiac arrhythmia (irregular heart beat), hypertension (high blood pressure), asthma, sleep apnea (suspension of breathing during sleep), diarrhea, and... (Source: NaturalNews.com)
Source: NaturalNews.com - December 19, 2017 Category: Consumer Health News Source Type: news
Spinal Elements lifts former COO Blain to the corner office | Personnel Moves November 30, 2017
Spinal Elements, previously known as Amendia, said this week it is lifting co-founder and current prez & COO Jason Blain to the position of prez & CEO, effective immediately. Prior to coming on to co-found Spinal Elements, Blain served in various roles with medtech companies Smith & Nephew (NYSE:SNN), Alphatec (NSDQ:ATEC) and NuVasive Inc. (NSDQ:NUVA). Blain is replacing Chris Fair, who will stay on as a board member with the company. “I am excited by the opportunity to lead our talented team of employees and partners and create an even more vibrant and dynamic Spinal Elements in the years ...
Source: Mass Device - November 30, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Abbott Alphatec Apica Cardiovascular Bovie Medical Corp. Cardiovascular Systems Inc. Dentsply Sirona Guidant Corp. Lima Corporate Medical Device Innovation Consortium MedLumics MedTech Europe Medtronic Nuv Source Type: news
Shining a light on the nervous system to thwart disease
(Case Western Reserve University) Researchers from Case Western Reserve University School of Medicine, Vanderbilt University, and University of Pittsburgh have received a four-year, $9 million grant from the National Institutes of Health to develop enhanced infrared light technology (infrared neuromodulation) for potentially treating a variety of diseases, including cardiac arrhythmias, high and low blood pressure, asthma, sleep apnea and diarrhea, one of the leading killers of children worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news
URMC Cardiologist Receives High Honor from American Heart Association
University of Rochester Medical Center cardiologist Arthur J. Moss, M.D., whose research on cardiac arrhythmias has saved countless lives and changed the treatment of heart disease worldwide, was honored with the 2017 James B. Herrick Award at the American Heart Association ’s Scientific Sessions. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 13, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Abbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S.
THE CONFIRM RX ICM COMBINES ADVANCED MEDICAL DEVICE WITH THE LATEST IN MOBILE AND DIGITAL TECHNOLOGY PHYSICIANS CAN REMOTELY MONITOR THEIR PATIENTS WITH CONFIRM RX FOR EVEN THE MOST DIFFICULT TO DETECT CARDIAC ARRHYTHMIAS, INCLUDING IRREGULAR HEARTBEATS... Devices, Monitoring, Cardiology, FDA, Product Launch Abbott, Confirm Rx, Insertable Cardiac Monitor, Cardiac Monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 23, 2017 Category: Pharmaceuticals Source Type: news